Basit öğe kaydını göster

dc.contributor.authorOzturk, Buket Caliskaner
dc.contributor.authorGEMİCİOĞLU, Bilun
dc.contributor.authorBÖREKÇİ, Şermin
dc.contributor.authorGencer, Aysegul
dc.date.accessioned2023-02-21T08:31:03Z
dc.date.available2023-02-21T08:31:03Z
dc.identifier.citationGencer A., Ozturk B. C., BÖREKÇİ Ş., GEMİCİOĞLU B., "Bronchodilator reversibility testing in long-term cough and dyspnea after Covid-19 viral infection: a trigger for asthma?", JOURNAL OF ASTHMA, 2022
dc.identifier.issn0277-0903
dc.identifier.othervv_1032021
dc.identifier.otherav_1c21b0d5-a69a-4f93-92fc-1bfabccf08a9
dc.identifier.urihttp://hdl.handle.net/20.500.12627/186733
dc.identifier.urihttps://doi.org/10.1080/02770903.2022.2139719
dc.description.abstractObjective: This study aims to investigate the presence of underlying chronic airway disease in individuals with chronic cough and dyspnea lasting longer than eight weeks and who had previously Coronavirus disease 2019 (COVID-19) and had no known lung disease. Methods: A total of 151 patients admitted to the respiratory diseases outpatient room with the complaint of cough and/or dyspnea that persisted for at least eight weeks following COVID-19 infection were accrued to the study. Demographic characteristics, smoking history, the severity of lung involvement on chest computed tomography in the acute phase of Covid-19 infection, and bronchodilator reversibility test results were recorded. Smoking history and forced expiratory volume in the first second (FEV1) were compared. Results: FEV1 increase >= 200 ml was observed in 40 (26.5%) patients. In 24 (15.9%) patients, an increase in FEV1 was found to be 200 ml and above, and the percentage of FEV1 was 12% or more. While 14 (9.3%) patients were diagnosed with asthma, 13 (8.6%) patients were diagnosed with nonreversible airflow obstruction (NRAO), and 1 (0.7%) patient was diagnosed with chronic obstructive pulmonary disease (COPD). Conclusions: COVID-19 infection may play a vital role in initiating asthma pathogenesis. It should be kept in mind that viral infection-related asthma may be the underlying cause of prolonged cough and dyspnea after COVID-19 infection.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectSolunum Bakımı
dc.subjectAkciğer ve Solunum Tıbbı
dc.subjectİmmünoloji ve Alerji
dc.subjectDahili Tıp Bilimleri
dc.subjectGöğüs Hastalıkları ve Allerji
dc.subjectTıp
dc.subjectSOLUNUM SİSTEMİ
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectALERJİ
dc.titleBronchodilator reversibility testing in long-term cough and dyspnea after Covid-19 viral infection: a trigger for asthma?
dc.typeMakale
dc.relation.journalJOURNAL OF ASTHMA
dc.contributor.departmentIstanbul Bakirkoy Dr Sadi Konuk Training & Res Ho , ,
dc.contributor.firstauthorID4078816


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster